Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Illumina fundamentals are improving, with FY26 expected to return to positive growth and enable operating leverage. Competition from Roche and others is a risk, but recent news appears priced in; shares have stabilized since the Roche Axelios reveal. FY26 guidance calls for 2% organic growth, EBIT margin expansion of 3% YoY, and further upside from the Somalogic acquisition.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Illumina gains after expanding Labcorp collaboration to boost NGS oncology adoption, broaden testing access, and drive growth in precision cancer care.
Bamco Inc. NY reduced its holdings in shares of Illumina, Inc. (NASDAQ: ILMN) by 15.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 208,094 shares of the life sciences company's stock after selling 39,378 shares during the period.
ILMN stock surges 44.8% in a year, fueled by NovaSeq X sequencing demand, broader NGS testing adoption, multiomics expansion and improving margins.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Illumina, Inc. (ILMN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.